<DOC>
	<DOCNO>NCT00686595</DOCNO>
	<brief_summary>This study evaluate efficacy , tolerability , effect quality life infliximab adult moderate-to-severe psoriasis resistant etanercept 12 week treatment fail 24 week treatment etanercept . Infliximab administer intravenous infusion 5 mg/kg Baseline ( Week 0 ) , Visit 3 ( Week 2 ) , Visit 4 ( Week 6 ) , Visit 6 ( Week 14 ) , Visit 8 ( Week 22 ) .</brief_summary>
	<brief_title>A Study Evaluate Switch From Etanercept Infliximab Subjects With Moderate-to-Severe Psoriasis ( Study P05133 )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>&gt; =18 75 year age Screening , either sex , race . Diagnosis moderatetosevere plaque psoriasis &gt; 6 month prior Screening . Resistant ( 12 week ) fail 24 week etanercept treatment . Not reach PASI 75 Screening Visit 24 week etanercept treatment resistant etanercept . Agree avoid prolong sun exposure artificial ultraviolet light source study . Satisfy requirement Screening tuberculosis ( TB ) test specify protocol . Chest xray Visit 1 within 3 month prior Visit 1 evidence malignancy , infection , fibrosis . Laboratory test must within protocolspecified parameter . Free clinically significant disease would interfere study evaluation . Willing participate adhere study procedure sign write informed consent . Women childbearing potential men must use adequate birth control measure continue 6 month receive last dose study medication . Females childbearing potential must negative serum pregnancy test Visit 1 negative urine pregnancy test Visit 2 . Achieve PASI 75 BSA &lt; 10 % 24 week etanercept . Current druginduced psoriasis . Females pregnant nursing male females plan pregnancy study period 6 month receive last dose study medication . Previously treat infliximab . Currently take take protocolspecified prohibit drug within specified time frame prior Baseline . Congestive Heart Failure ( CHF ) Chronic recurrent infectious disease . Have serious infection , hospitalize receive IV antibiotic infection 2 month prior Visit 1 . Have opportunistic infection within 6 month prior Visit 1 . Have herpes zoster infection within 2 month prior Visit 1 . Human Immunodeficiency Virus ( HIV ) , hepatitis B C. History clinically significant adverse event ( AEs ) murine chimeric protein human/murine recombinant product . Current sign symptom severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological , cerebral , psychiatric disease . History demyelinate disease symptom suggestive multiple sclerosis optic neuritis . Current sign symptom history systemic lupus erythematosus . Transplanted organ ( exception corneal transplant &gt; 3 month prior Visit 1 ) . History lymphoproliferative disease , include lymphoma , sign symptom suggestive possible lymphoproliferative disease , lymphadenopathy unusual size location . Malignancy within previous 5 year ( exception basal cell carcinoma skin treat evidence recurrence ) . Unable unwilling undergo multiple venipuncture poor tolerability lack easy access vein . Have substance abuse ( drug alcohol ) problem within previous 3 year . History clinically significant adverse reaction ( include allergic reaction ) paracetamol/acetaminophen histamine H1 receptor antagonist . In situation condition , opinion investigator , may interfere optimal participation study . Used investigational drug within 4 week Screening . Participating clinical study . Staff personnel directly involve study . Family member investigational study staff .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>